-
-
-
Sequence Name
- D2A21(Demegal)
-
Description
- a 22-residue αhelix peptide
-
-
Medical use
- Anti-infective and antifungal
-
Stage of Development
- Preclinical
-
- 100% for the D2A21-treated animals, 50% for control-treated animals, 83% for Sulfamylon-treated animals, and 33% for SSD-treated animals.
-
Company
- Par Advance Technologies, Inc.
-
Target Organism
-
- The MCC(minimum cidal concentration of C. trachomatis) of peptide D2A21was 5 μM (18.32 μg/ml).The MCC of gel formulations containing 2% D2A21 was 0.2 mM (0.7 mg/ml).
-
Reference
-
- Antimicrobial peptides: therapeutic potential. Expert Opin. Pharmacother. (2006).
- In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis.Antimicrob. Agents Chemother(2002).(PMID: 11751108)
- Treatment of infected wounds with the antimicrobial peptide D2A21.JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE(2003)(PMID: 12707542)